NASDAQ OMX

Medibio building credentials to "scale" via appointment of healthcare & telehealth icon to Board of Directors

Dela

SYDNEY, Australia and MINNEAPOLIS, July 19, 2017 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), a digital health company that has developed an objective testing system to assist in the screening, diagnosis and treatment effectiveness of depression, chronic stress and other mental health disorders, is pleased to announce the appointment of Dr Adam Darkins, MB, ChB., MPHM, M.D., FRCS to the Board of Directors as Deputy Chairman. Dr Darkins has unique experience in taking national and trans-national virtual care delivery systems to scale.

Medibio Board member and fellow physician, Dr Frank Prendergast, M.D. said, "Adam is a wonderful addition to the Medibio Board. He complements our team, drawing on a wealth of experience gained from the practice of medicine, health care management, and having built one of the world's largest, telehealth programs. His proven track-record in tackling one of the current greatest healthcare challenges - how to introduce transformational new technologies that demonstrably increase access to care and reduce its cost - is what makes him so unique. His creativity and rigour, in design, and continuing development, of innovative care systems will help guide Medibio to meet anticipated milestones in our growth trajectory as we transition from clinical validation to regulatory approval, and then commence broader implementations. Adam will help us to lay the strategic foundations for large-scale operations in the pre-eminent health care systems of the future."     

Dr Darkins developed an extensive understanding of patient care, clinical processes, and outcomes measurement from his physician training at Manchester University Medical School, UK, and further training/accreditation as a neurosurgeon and researcher at UCLA. Studying public health medicine at the London School of Hygiene and Tropical Medicine, and pioneering shared patient decision-making programs at the King's Fund, London, grounded him in leading transformative change with a particular talent for safely and effectively taking long-established hospital-based practice into primary care, community care and non-traditional settings. Thereafter, already renowned for his ability to utilise new information and telecommunication technologies to empower patients, increase access to care and reduce cost, he gained widespread US and international recognition for his leadership of telehealth programs at the US Department of Veterans Affairs (VA). At VA he developed health informatics, telehealth and disease management technologies to enhance and extend care and case management. Together with his team, Dr Darkins created a capacity that delivered virtual services to more than 480,000 Veteran patients each year via 1.4 million episodes of care. On any given day, 83,000 Veteran patients were using home-telehealth technologies to live independently at home and avoid institutional care.

Dr Darkins comes to Medibio from Medtronic Plc where, as Vice President for Innovation and Strategic Partnerships for the Americas Region, he worked on using new payment models to transform health care. He has been permanently based in the USA since 1997. Dr Darkins serves on the editorial board of Telehealth and e-Health Journal; is a former Medical Director in London; co-founded a start-up telehealth company; and has both written, and spoken widely on how to address the challenges and find solutions in establishing large virtual health care networks that meet major health care priorities and deliver high volumes of patient consultation/care as their return on investment.  

Medibio CEO, Jack Cosentino said, "We are thrilled to have Dr Darkins join the Medibio board. As a visionary leader in telehealth, he shares our Company's passion for solving one of the world's most significant health epidemics. His experience in building virtual care systems will help us to address the significant, yet under-recognised need for mental health support services globally. His expertise and achievements in the telehealth, IOT and patient care arenas, and leadership experience at organisations, including the UK National Health Service, U.S. Department of Veterans Affairs and Medtronic, complements an incredible team we are developing at Medibio, to exclusively focus on meeting this global need. We look forward to leveraging his knowledge, insights and relationships to heighten Mental Health awareness and identifying ways to reduce the stigma and isolation it can cause."

Medibio Chairman, Chris Indermaur stated,  "We welcome Adam to the board of Medibio and value the addition of his leadership and passion to ours, as we collectively serve people with mental health conditions and seek to meet their aspirations for wellness and recovery."

Further Information: www.medibio.com.au
Medibio Shareholder Enquiries:
Jack Cosentino
CEO and Managing Director Medibio Limited
jack.cosentino@medibio.com.au
T: +1 952 465 4787
Investor Relations Enquiries:
Peter Taylor 
NWR Communications
peter@nwrcommunications.com.au 
T: +61 (0)412 036 231

About Medibio Limited
Medibio (ASX:MEB) (OTCQB:MDBIF) is a digital health company that has developed an objective test to assist in the diagnosis of depression, chronic stress and other mental health disorders. Based on research conducted over 15 years at the University of Western Australia, this test utilises patented (and patent pending) circadian heart rate variability and cloud based proprietary algorithms to deliver a quantifiable measure to assist in clinical diagnosis. Medibio's depression diagnostic is being validated in clinical studies undertaken by Johns Hopkins University School of Medicine and The University of Ottawa, among others. The clinical trials will support Medibio's application to become the first FDA approved, objective, and evidence-based approach to the diagnosis of mental health disorders. Medibio's technology also provides an objective method for the assessment of stress and mental wellbeing that can be translated to the workplace stress/wellbeing market, wearable technology and App market. Medibio was founded in Perth, Australia with offices located in Melbourne (VIC), and U.S. offices in Minneapolis, MN and Palo Alto, CA.  Medibio is listed on the Australian Securities Exchange Ltd (ASX) and trades on the OTCQB Venture Market.  Investors can find Real-Time quotes and market information for the company on www.otcmarkets.com and www.asx.com.au




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medibio Limited via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II combination study with APR-246 at hematology congress17.6.2018 06:05Pressmeddelande

STOCKHOLM, June 17, 2018. Karolinska Development's portfolio company Aprea Therapeutics presents continued positive development for the candidate drug APR-246 in patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 European Hematology Association (EHA) Annual Meeting in Stockholm. The presentation at EHA follows the positive results presented at the 2018 American Association of Cancer Research (AACR) Annual Meeting in Chicago in April. The results from the Phase Ib/II combination study with APR-246 and azacitidine show an overall response rate (ORR) of 100 per cent in 9 evaluable patients, with 8 patients achieving a complete response (CR) and 1 patient achieving a marrow complete response (mCR). Conclusive data on Median progression free survival (PFS) and overall survival (OS) have not yet been obtained in the study. Adverse Events (AEs) during the APR-246 monotherapy lead-in phase were all grade 1 or grade 2. No dose limiting toxicities have been experienced to date

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II combination study with APR-246 at hematology congress17.6.2018 06:05Pressmeddelande

STOCKHOLM, June 17, 2018. Karolinska Development's portfolio company Aprea Therapeutics presents continued positive development for the candidate drug APR-246 in patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 European Hematology Association (EHA) Annual Meeting in Stockholm. The presentation at EHA follows the positive results presented at the 2018 American Association of Cancer Research (AACR) Annual Meeting in Chicago in April. The results from the Phase Ib/II combination study with APR-246 and azacitidine show an overall response rate (ORR) of 100 per cent in 9 evaluable patients, with 8 patients achieving a complete response (CR) and 1 patient achieving a marrow complete response (mCR). Conclusive data on Median progression free survival (PFS) and overall survival (OS) have not yet been obtained in the study. Adverse Events (AEs) during the APR-246 monotherapy lead-in phase were all grade 1 or grade 2. No dose limiting toxicities have been experienced to date

INVNT/IP: US Responds to Nation-sponsored Crown-jewel Intellectual Property Theft15.6.2018 23:34Pressmeddelande

US Announcement of Large-Scale Tariffs in Response to Chinese Crown-Jewel Intellectual Property Theft Lauded by IP Protection Consortium INVNT/IP SEATTLE, June 15, 2018 (GLOBE NEWSWIRE) -- The Trump administration today announced 25% tariffs on $50 billion in Chinese goods, representing the first time the United States government has marked sectors in US-China trade for retaliation as a response to theft of crown-jewel intellectual property. In a public statement, President Trump announced that the measures were targeted toward goods that "contain industrially significant technologies." US Trade Representative Robert Lighthizer applauded the move on Fox News, noting, "It's thorough. It's moderate. It's appropriate." In a further explanation of the move, he added, "What I want to do is make sure that we protect our technology here at home, that we stop cybertheft and forced technology transfer, and ultimately, remember: 'China 2025' is a $300 billion subsidy program. The United States h

Brookfield Asset Management Announces Results of Annual and Special Meeting of Shareholders15.6.2018 22:30Pressmeddelande

BROOKFIELD, NEWS, June 15, 2018 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (TSX:BAM.A) (NYSE:BAM) (Euronext:BAMA) today announced that at the company's annual and special meeting of shareholders held earlier today in Toronto, approximately 92% of Class A Limited Voting Shares ("Class A Shares") voted in favour of an advisory vote approving the company's approach to executive compensation. In addition, at the meeting all eight nominees proposed for election to the board of directors by holders of Class A Shares and all eight nominees proposed for election to the board of directors by the holder of Class B Limited Voting Shares ("Class B Shares") were elected. Detailed results of the vote for the election of directors are set out below. Management received the following proxies from holders of Class A Shares in regard to the election of the eight directors nominated by this shareholder class: Director Nominee Votes For % Votes Withheld % M. Elyse Allan 620,669,437 99.53 2,921,9

NEP Completes Acquisition of Telerecord15.6.2018 13:53Pressmeddelande

FLORENCE, Italy, June 15, 2018 (GLOBE NEWSWIRE) -- Today NEP Group, a leading outsourced technical production partner supporting premier content producers of live sports and entertainment, announced that it has completed its acquisition of Telerecord, an Italy-based provider of outside broadcast solutions. Telerecord, a local industry leader with strong client relationships, covers popular sporting events in Italy and throughout Southern Europe including football, ice hockey and bobsleigh. The deal further diversifies NEP's business and expands its reach in Europe by adding additional local resources and talent. As part of the deal, all Telerecord staff members will join NEP. Telerecord will be rebranded as NEP and will be part of NEP Italy, which is led by Sergio Cecchini, GM of NEP Italy, who joined NEP in May. Telerecord also brings a fleet of several outside broadcast trucks, sprinter vans and motorcycles to the NEP Worldwide Network to serve clients across Europe. "We couldn't be

Fortuna Reports Results of Annual General Meeting15.6.2018 11:00Pressmeddelande

VANCOUVER, British Columbia, June 15, 2018 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE:FSM) (TSX:FVI) hereby announces the voting results at the Company's annual general meeting held on June 14, 2018. A total of 108,538,241 common shares were represented at the meeting, being 68% of the Company's issued and outstanding shares. Shareholders voted in favour of all matters brought before the meeting including the appointment of auditors, the election of management's nominees as directors, and the ratification and approval of the Company's amended Advance Notice Policy. Detailed results of the votes on the election of directors are as follows: Director Votes For Votes Withheld Jorge Ganoza Durant Simon Ridgway Mario Szotlender David Farrell David Laing Alfredo Sillau Kylie Dickson 74,947,635 (97.4%) 63,448,600 (82.5%) 70,831,225 (92.1%) 74,816,864 (97.3%) 73,597,731 (95.7%) 75,716,342 (98.4%) 76,476,115 (99.4%) 1,930,230 (2.5%) 13,429,266 (17.4%) 6,046,640 (7.9%) 2,061,001 (2.7%) 3

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum